OneSource Specialty Pharma Ltd

{"description":"OneSource Specialty Pharma shares fell over 5% after Q4FY26 profit plunged to ₹4.6 crore from ₹98.5 crore, EBITDA halved, margins fell to 21.5%, and FY26 swung to a ₹73.8 crore loss.","url":"https://www.cnbctv18.com/market/earnings/onesource-specialty-pharma-share-price-falls-q4-profit-plunges-margins-halve-ws-l-19904760.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"Onesource Specialty Pharma shares fell 18% due to a delay in semaglutide approval in Canada, leading to a significant revenue shortfall in Q3 FY26. Despite this, management maintains long-term growth prospects and reaffirmed FY28 guidance of ₹40,000 crore in organic revenue.","url":"https://www.cnbctv18.com/market/onesource-specialty-pharma-share-price-tanks-18-percent-after-semaglutide-delay-hurts-q3-performance-ws-l-19833773.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"OneSource Specialty Pharma has raised its FY28 revenue guidance from $400 million to over $500 million, driven by strong demand for weight-loss drugs. The company plans a $100 million capacity expansion to capitalize on the anticipated market boom, particularly for semaglutide, with completion expected in 2026.","url":"https://www.livemint.com/companies/news/onesource-weight-loss-drug-prospects-fy28-revenue-guidance-to-over-500-mn-11762959009112.html","sentiment":"Positive","domain":"Mint"}